ArticleJournal of immunotherapy (Hagerstown, Md. : 1997)
A dose-escalation study of recombinant human interleukin-18 in combination with rituximab in patients with non-Hodgkin lymphoma.
Article in Journal of immunotherapy (Hagerstown, Md. : 1997). The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00500058 (A Phase I, Dose-Escalation Study to Assess the Safety and Biological Activity of Recombinant Human Interleukin-18), which is not on this map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase I, Dose-Escalation Study to Assess the Safety and Biological Activity of Recombinant Human Interleukin-18 (SB-485232) Administered by Intravenous Infusion in Combinationwith Rituximab in Adult Patients With B Cell Non-Hodgkin'sLymphoma"
Who cites it
20 citing papers in PubMed, 40 citations in OpenAlex.
- Engineered IL-18 variants with half-life extension and improved stability for cancer immunotherapy.Journal for immunotherapy of cancer · 2025Article
- Durable antitumor response via an oncolytic virus encoding decoy-resistant IL-18.Journal for immunotherapy of cancer · 2024Article
- Role of Non-Binding T63 Alteration in IL-18 Binding.International journal of molecular sciences · 2024Article
- Development of Innate-Immune-Cell-Based Immunotherapy for Adult T-Cell Leukemia-Lymphoma.Cells · 2024Article
- Synthetic Cells and Molecules in Cellular Immunotherapy.International journal of biological sciences · 2024Review
- Harnessing natural killer cells for cancer immunotherapy: dispatching the first responders.Nature reviews. Drug discovery · 2022Review
- Cytokine Based Immunotherapy for Cancer and Lymphoma: Biology, Challenges and Future Perspectives.Frontiers in immunology · 2022Review
- Article
- Review
- Interleukin-18 in Health and Disease.International journal of molecular sciences · 2019Review
- IL-1 Family Members in Cancer; Two Sides to Every Story.Frontiers in immunology · 2019Review
- A Dose-escalation Study of Recombinant Human Interleukin-18 in Combination With Ofatumumab After Autologous Peripheral Blood Stem Cell Transplantation for Lymphoma.Journal of immunotherapy (Hagerstown, Md. : 1997) · 2018Article
- Resolution of Cancer-Promoting Inflammation: A New Approach for Anticancer Therapy.Frontiers in immunology · 2017Review
- The IL-15-Based ALT-803 Complex Enhances FcγRIIIa-Triggered NK Cell Responses and In Vivo Clearance of B Cell Lymphomas.Clinical cancer research : an official journal of the American Association for Cancer Research · 2016Article
- Sézary Syndrome and Atopic Dermatitis: Comparison of Immunological Aspects and Targets.BioMed research international · 2016Review
- γδ T Cell Immunotherapy-A Review.Pharmaceuticals (Basel, Switzerland) · 2015Review
- Classification of current anticancer immunotherapies.Oncotarget · 2014Review
- Utilizing cytokines to function-enable human NK cells for the immunotherapy of cancer.Scientifica · 2014Review
- Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 5 institutions in 1 country.
Funding
Abstract
Interleukin-18 (IL-18) is an immunostimulatory cytokine with antitumor activity in preclinical models. Rituximab is a CD20 monoclonal antibody with activity against human B-cell lymphomas. A phase I study of recombinant human (rh) IL-18 given with rituximab was performed in patients with CD20+ lymphoma. Cohorts of 3-4 patients were given infusions of rituximab (375 mg/m2) weekly for 4 weeks with escalating doses of rhIL-18 as a 2-hour intravenous infusion weekly for 12 consecutive weeks. Toxicities were graded using standard criteria. Blood samples were obtained for safety, pharmacokinetic, and pharmacodynamic studies. Nineteen patients with CD20+ B-cell non-Hodgkin lymphoma were given rituximab in combination with rhIL-18 at doses of 1, 3, 10, 20, 30, and 100 μg/kg. Common side effects included chills, fever, headache, and nausea. Common laboratory abnormalities included transient, asymptomatic lymphopenia, hyperglycemia, anemia, hypoalbuminemia, and bilirubin and liver enzyme elevations. No dose-limiting toxicities were observed. Biologic effects of rhIL-18 included transient lymphopenia and increased expression of activation antigens on lymphocytes. Increases in serum concentrations of IFN-γ, GM-CSF, and chemokines were observed after dosing. Objective tumor responses were seen in 5 patients, including 2 complete and 3 partial responses. rhIL-18 can be given in biologically active doses by weekly infusions in combination with rituximab to patients with lymphoma. A maximum tolerated dose of rhIL-18 plus rituximab was not determined. Further studies of rhIL-18 and CD20 monoclonal antibodies in B-cell malignancies are warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.